On October 7, 2026 Affibody Medical AB ("Affibody"), a clinical stage biotechnology company developing next generation radiopharmaceuticals, reported that management will participate in the 6th Annual Needham Private Biotech & Medtech Company Virtual 1×1 Forum, taking place October 13–14, 2026. Affibody will be represented by David Bejker, Chief Executive Officer, and Peter Zerhouni, Chief Financial Officer and Chief Business Officer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During the forum, management will be available for one-on-one meetings with investors and will discuss Affibody’s precision radioligand therapy platform, including the ongoing clinical development of its lead HER2-targeted candidate, ABY-271, and its emerging pipeline of RLT programs for solid tumors.

(Press release, Affibody, OCT 7, 2026, View Source;1-forum/ [SID1234673259])